How do I buy Arrowhead Pharma (ARWR) stock?

Buying Arrowhead Pharma (ARWR) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "ARWR", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy ARWR by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if ARWR is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Arrowhead Pharma (ARWR) Stock

Q: What is the minimum investment for ARWR on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Arrowhead Pharma from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NSQ · ARWR

Trade ARWR

Key stats

Market cap: $6.97B
Price / Earnings ratio: -21.6x
EPS (TTM): -$2.25
Volume: Loading
52-week high: $95.49
52-week low: $37.06
EPS vs analyst estimate: -260.0%Q4 FY25 · -$0.18 vs -$0.05
Next earnings report: 24 Nov 2026

Source: third-party data provider, as of November 13, 2026

EPS estimate: analyst consensus

Compare with ARWR

Technical indicators

RSI 14: 26.29
MACD 12/26/9: -3.41
EMA 9 of MACD: -2.78
MACD histogram: -0.63
SMA 50: $64.86; Price below SMA 50
EMA 50: $63.75; Price below EMA 50
SMA 200: $71.28; Price below SMA 200
EMA 200: $67.74; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 6 analyst ratings

Strong Sell0

Sell0

Hold1

Buy5

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

995M657M328M0

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

2B1B549M0

Revenue to Profit

2025

$829.4M

Revenue

$0.0

Cost of revenue

$829.4M

Gross profit

$0.0

Operating expenses

$-1.6M

Net income

Earnings

EPS forecast

Actual EPS

$-0.18

$-0.05

Q4FY25

$0.21

Q1FY26

$-0.98

Q2FY26

$-1.22

Q3FY26

$-1.24

Q4FY26

The market is expecting earnings per share of -$1.24 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About Arrowhead Pharma

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

SectorHealthcare

IndustryBiotechnology

Employees711

CEODr. Christopher R. Anzalone Ph.D.

IPO DateJun 16, 1993

HeadquartersPasadena, CA

Key Executives

Name	Title	Year Born
Dr. Christopher R. Anzalone Ph.D.	Chairman, CEO & President	1969
Mr. Daniel J. Apel	Chief Financial Officer	1966
Mr. Patrick O'Brien J.D., PharmD	COO & Secretary	1964
Dr. James C. Hamilton M.D., MBA	Chief Medical Officer and Head of R&D	1979
Dr. Mark M. Davis Ph.D.	Founder and Founder & Director of Insert Therapeutics Inc & Calando	—
Dr. Tao Pei Ph.D.	Chief Scientific Officer	—
Dr. Vincent Anzalone CFA	Head of Investor Relations & VP	—
Mr. Howard Lovy	Director of Communications	—
Dr. Bruce D. Given M.D.	Chief Medical Scientist	1954
Dr. Mark Seefeld	Head of Toxicology & VP	1954

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											+6.3	-1.0
2022	-24.6	-20.1	+3.8	-16.4	-22.5	+6.5	+18.3	-4.9	-20.0	+3.2	-9.3	+26.7
2023	-9.1	-8.5	-22.2	+38.5	-3.7	+2.9	-1.9	-17.9	-3.9	-6.3	-17.8	+32.1
2024	+3.5	-0.3	-20.7	-19.9	-0.9	+5.6	+9.6	-13.2	-15.5	+0.3	+33.6	-28.6
2025	+1.2	+0.9	-28.1	+13.8	+14.5	-3.7	-1.8	+38.3	+34.3	+21.1	+33.0	+18.0
2026	+2.3	-13.3	-2.5	+16.8	+4.1	+8.4	+5.2	-4.2	-20.9	-7.5	-17.1

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Arrowhead Pharma (ARWR) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and verify your identity.
Make a deposit.
Search for the code "ARWR", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy ARWR by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full share. With fractional shares, you can start investing in Arrowhead Pharma from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Arrowhead Pharma (ARWR) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track ARWR's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too.

The market is closed on US public holidays. The Gotrade app shows whether the market is open.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Arrowhead Pharma (ARWR) Stock

Key stats

Compare with ARWR

Recent news

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study

Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study

Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study

Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know

Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress

Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress

About Arrowhead Pharma

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade